Literature DB >> 12021778

MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo.

Astrid Krmpotić1, Dirk H Busch, Ivan Bubić, Friedemann Gebhardt, Hartmut Hengel, Milena Hasan, Anthony A Scalzo, Ulrich H Koszinowski, Stipan Jonjić.   

Abstract

The susceptibility of certain inbred mouse strains to murine cytomegalovirus (MCMV) is related to their inability to generate a strong natural killer (NK) cell response. We addressed here whether the MCMV susceptibility of the BALB/c strain is due to viral functions that control NK cell activation in a strain-specific manner. MCMV expresses two proteins, gp48 and gp40, that are encoded by the genes m06 and m152, respectively; they down-regulate major histocompatibility complex (MHC) class I expression at the plasma membrane. Using MCMV deletion mutants and revertants, we found that gp40 but not gp48 controls NK cell activation. Absence of gp40 improved antiviral NK cell control in BALB/c, but not C57BL/6, mice. Down-regulation of H-60, the high-affinity ligand for the NKG2D receptor, was the mechanism by which gp40 modulates NK cell activation. Thus, a single herpesvirus protein has a dual function in inhibiting both the adaptive as well as the innate immune response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021778     DOI: 10.1038/ni799

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  80 in total

1.  Transient CD8-memory contraction: a potential contributor to latent cytomegalovirus reactivation.

Authors:  Jonathan Campbell; Joanne Trgovcich; Michelle Kincaid; Peter D Zimmerman; Paul Klenerman; Stuart Sims; Charles H Cook
Journal:  J Leukoc Biol       Date:  2012-06-22       Impact factor: 4.962

Review 2.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

3.  Regulation of CD1d expression and function by a herpesvirus infection.

Authors:  David Jesse Sanchez; Jenny E Gumperz; Don Ganem
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

Review 4.  NKG2D in NK and T cell-mediated immunity.

Authors:  Kouetsu Ogasawara; Lewis L Lanier
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

5.  Cytomegalovirus encodes a positive regulator of antigen presentation.

Authors:  Rafaela Holtappels; Dorothea Gillert-Marien; Doris Thomas; Jürgen Podlech; Petra Deegen; Sylvia Herter; Silke A Oehrlein-Karpi; Dennis Strand; Markus Wagner; Matthias J Reddehase
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells.

Authors:  Valentina Voigt; Catherine A Forbes; Joanne N Tonkin; Mariapia A Degli-Esposti; Hamish R C Smith; Wayne M Yokoyama; Anthony A Scalzo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

Review 7.  Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy.

Authors:  William Britt
Journal:  Med Microbiol Immunol       Date:  2015-03-13       Impact factor: 3.402

Review 8.  Herpesvirus Evasion of Natural Killer Cells.

Authors:  Steffi De Pelsmaeker; Nicolas Romero; Massimo Vitale; Herman W Favoreel
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

9.  Characterization of murine cytomegalovirus m157 from infected cells and identification of critical residues mediating recognition by the NK cell receptor Ly49H.

Authors:  Aja H Davis; Natalya V Guseva; Brianne L Ball; Jonathan W Heusel
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Immune evasion proteins of murine cytomegalovirus preferentially affect cell surface display of recently generated peptide presentation complexes.

Authors:  Niels A W Lemmermann; Kerstin Gergely; Verena Böhm; Petra Deegen; Torsten Däubner; Matthias J Reddehase
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.